FDA Pipeline Preview
FDA Grants Full Approval to Rybrevant in Lung Cancer
Rybrevant is indicated to be used in combination with chemotherapy as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer.
HHS Issues Guidance for Medicare Prescription Drug Payment Plan
Beginning in 2025, people with Medicare Part D drug coverage will have the option to pay out-of-pocket costs in monthly payments spread out over the year.
Mercer Launches Technology Solution for Specialty Drugs
Mercer has teamed up with Free Market Health to offer employers Mercer SelectRx, which searches a network of specialty pharmacies for the lowest price on specialty medications.
FDA Sets Date for Full Approval of Ocaliva in Liver Disease
The target action date is Oct. 15, 2024, for full approval of Ocaliva to treat patients with primary biliary cholangitis. The FDA is planning to hold an advisory committee meeting to discuss the application.
Glaukos Launches Implantable Glaucoma Treatment
iDose TR was approved to reduce intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It has a wholesale acquisition cost of $13,950 per dose/implant.
FDA Sets Action Date for Axatilimab in Graft-Versus-Host Disease
The Prescription Drug User Fee Act action date is Aug. 28, 2024.
2 Commerce Drive Cranbury, NJ 08512